Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / Why Private Equity Is Buying Up Independent Pharmacies
Transcript
- Lucas: If you walk down Main Street in almost any mid-sized American town, you will still see a sign that says 'Family Pharmacy' or 'Main Street Drugs' — a single-location independent pharmacy that has been there for decades, often owned by a local pharmacist. Luna: And increasingly, that sign is being bought by a private equity-backed entity that owns 40 other signs just like it. Lucas: Exactly. Independent pharmacies are the latest target in the consolidation wave we've been tracking all season — and it makes a lot of economic sense once you dig into the numbers. Luna: So what's the pitch? Why does a PE firm want a bunch of small pharmacy stores? Lucas: The core thesis is that independent pharmacies are high-cash-flow businesses with a sticky, local customer base, but they operate on razor-thin margins because they lack purchasing power. A single store doing — say — $4 million in revenue might clear only $400,000 in EBITDA. That's 10 percent. Luna: And the PE firms think they can fix that. Lucas: They do. The classic roll-up logic: consolidate purchasing, centralize back-office, negotiate better rates with pharmacy benefit managers — PBMs — and suddenly that same store can produce 18 to 20 percent EBITDA margins. On a 50-store platform, that's serious cash flow. Luna: I've heard of a specific group — investors from Oak Street Health's original team — that is building a pharmacy roll-up called 'Alto' something? Lucas: You are thinking of Alto Pharmacy. Although that one started as a tech-forward digital pharmacy, the roll-up model for independents is being led by a firm called 'Guardian Pharmacy Services' — they've gone public now, actually. But there are dozens of private ones: 'Capsule', 'NowRx', 'Medly' — all backed by PE. Luna: And the numbers work because the stores are already profitable. The PE firm just makes them more profitable. Lucas: Right. The acquisition multiple for a typical independent pharmacy is around 5 to 7 times EBITDA — relatively cheap compared to, say, a software company. If you can buy at 6 times and, through centralization, grow EBITDA by 40 percent, your effective multiple drops to 4.3 times. That's a compelling entry point. Luna: But there's a catch — the regulatory environment. Lucas: There is. The Federal Trade Commission has been investigating PBM practices. PBMs control about 80 percent of prescription drug reimbursement in the US. Independent pharmacies say PBMs under-reimburse them, and PE consolidation is partly a response to that pressure — you need scale to have a seat at the negotiating table. Luna: Quick honest thing — episodes like this one, where we go deep into a specific roll-up model, take a lot of research time. A handful of listeners chip in monthly through Buy Me a Coffee dot com slash Fexingo, and that literally funds making this many of these. Lucas: Yeah, it's a small group, but it keeps us ad-free and able to spend the hours pulling together these deal sheets. If these conversations have moved your work forward in some small way, that link is Buy Me a Coffee dot com slash Fexingo. Luna: And we appreciate every single one of you who does. So, back to the pharmacy story — there is also a demographic angle, right? Lucas: There is. The average independent pharmacist owner is in their mid-50s. Many don't have a clear succession plan. PE comes in with an offer that values their life's work at a multiple of earnings, plus a earn-out where the pharmacist stays on for two or three years. It's a retirement solution. Luna: So the seller gets liquidity, the PE firm gets the cash flow. Seems like a win-win. Lucas: It is, until you look at what happens to the patient. Critics argue that when PE owns the pharmacy, you see more aggressive generic substitution, higher dispensing fees, and less willingness to stock low-margin drugs. There was a study from the Journal of the American Medical Association last year showing that pe owned pharmacies were 30 percent more likely to dispense a high-margin medication over a clinically equivalent cheaper one. Luna: That is a real tension. The model works financially, but the patient experience can degrade. Lucas: And that's why you see some states — like Ohio and New York — introducing bills that require disclosure when a pharmacy is owned by a private equity firm. The argument is that patients should know if their local drugstore is now part of a profit-maximizing chain. Luna: So what's the size of the opportunity? How many independent pharmacies are left? Lucas: Roughly 22,000 independent pharmacies in the United States, according to the National Community Pharmacists Association. That's about a third of all retail pharmacies. And they fill about 40 percent of all prescriptions. So it's a massive addressable market for consolidation. Luna: And how many have been bought so far? Lucas: The estimates are that around 15 to 20 percent of independents are now owned by pe backed groups. That number has doubled since 2020. The pace is accelerating. Luna: I wonder if the PBM reform that might come from Washington could slow this down. Lucas: It could. If PBMs are forced to reimburse at a higher rate, independent margins improve without needing scale. That would reduce the urgency to sell. But the window for that legislation is uncertain — and in the meantime, the deal flow continues. Luna: Let's talk about one specific deal structure. How does a typical pharmacy roll-up actually finance the acquisitions? Lucas: It's a classic leveraged buyout structure. The PE firm puts in 30 to 40 percent equity, the rest is debt — often a combination of a senior term loan from a bank and a mezzanine tranche from a specialty lender. The target's cash flow services the debt. The key metric is debt to ebitda — they want it under 4.5 times. Luna: And the debt is secured against the pharmacy's inventory and receivables. Lucas: Exactly. Inventory is relatively liquid — drugs have a market — so lenders are comfortable. That's part of why pharmacies are attractive collateral. Luna: So if the model works, and the debt gets paid down, the PE firm exits in 5 to 7 years, either through a sale to a larger strategic or an IPO. Lucas: That's the plan. But there are risks. One is the talent risk — you need to retain the pharmacist managers. Another is reimbursement risk — if Medicare or Medicaid cuts reimbursement rates, the whole model squeezes. And then there's the threat of Amazon. Luna: Amazon Pharmacy has been growing. They offer two-day delivery and discounts for Prime members. Lucas: Right. But Amazon is targeting the chronic medication refill market — the easy stuff. Independent pharmacies thrive on the acute, the complex, the compounded, the personal relationship. A patient with six medications who needs counseling is not going to Amazon. At least not yet. Luna: So the PE bet is that the local pharmacist relationship has real defensive value. Lucas: That's the thesis. And so far, the numbers back it up. The roll-ups that have been around for five or six years — like Guardian — have grown EBITDA consistently. Guardian went public in 2024, and their same-store sales growth has been mid-single digits year over year. Luna: Enough to keep the LPs happy. Lucas: And to attract more capital. I saw a deal flow report last month that showed pharmacy services was the second most active sub-sector in healthcare services M&A in the first quarter of 2026, just behind dental. Luna: So if you're a pharmacist looking at retirement, the offer is probably on the table. Lucas: It is. And if you're a PE firm looking for a fragmented, recession-resistant, cash-flowing industry, the pharmacy shelf is well stocked. Luna: I guess the question is whether the model can withstand the regulatory headwinds and the Amazon tailwinds. But for now, the numbers are compelling. Lucas: They are. And we'll keep watching whether the FTC's next move shifts the math. That's the interesting part — this is a live experiment in whether scale can fix the structural problems of independent pharmacy, or whether it just creates new ones.